Rheumatoid arthritis

Lancet

Volumn 358, Issue 9285, 2001, Pages 903-911

  Lee, David M ^a   Weinblatt, Michael E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; ANTIRHEUMATIC AGENT; CELECOXIB; CELL ADHESION MOLECULE; CHEMOKINE; CYCLOSPORIN A; CYTOKINE; ETANERCEPT; FOLIC ACID; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 2 RECEPTOR; LEFLUNOMIDE; MATRIX METALLOPROTEINASE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; SALAZOSULFAPYRIDINE; SERINE PROTEINASE INHIBITOR; TERIFLUNOMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANGIOGENESIS; CLINICAL FEATURE; CLINICAL TRIAL; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DRUG APPROVAL; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; GENETIC MARKER; HISTOPATHOLOGY; HUMAN; JOINT DESTRUCTION; MONOTHERAPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 0035883897     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)06075-5     Document Type: Review

References (93)

1. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset
2. The relationship between synovitis and bone changes in early untreated rheumatoid arthritis: A controlled magnetic resonance imaging study
3. Immunohistological features in the synovium obtained from clinically uninvolved knee joints of patients with rheumatoid arthritis
4. Radiographic outcome of recent-onset rheumatoid arthritis: A 19-year study of radiographic progression
5. Long-term course and outcome of functional capacity in rheumatoid arthritis: The effect of disease activity and radiologic damage over time
6. Occurrence of rheumatoid arthritis in a nationwide series of twins
7. Twin concordance rates for rheumatoid arthritis: Results from a nationwide study
8. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins
9. Heterogeneity of disease phenotype in monozygotic twins concordant for rheumatoid arthritis
10. HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region
11. Rheumatoid arthritis may be primarily associated with HLA-DR4 molecules sharing a particular sequence at residues 67-74
12. Genetic epidemiology of rheumatoid disease
13. The genetics revolution and the assault on rheumatoid arthritis
14. High endothelial venules (HEVs): Specialized endothelium for lymphocyte migration
15. Morphologic observations in the early phase of the cartilage-pannus junction: Light and electron microscopic studies of active cellular pannus
16. Localization of collagenase mRNA in rheumatoid arthritis synovium by in situ hybridization histochemistry
17. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium
18. Electron microscopic studies of the cartilage-pannus junction in rheumatoid arthritis
19. Anchorage-independent growth of synoviocytes from arthritic and normal joints: Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids
20. The immunohistologic features of synovitis, disease activity and in vitro IgM rheumatoid factor synthesis by blood mononuclear cells in rheumatoid arthritis
21. T cell receptor V beta gene bias in rheumatoid arthritis
22. The T-cell-receptor repertoire in the synovial fluid of a patient with rheumatoid arthritis is polyclonal
23. Perturbation of the T cell repertoire in rheumatoid arthritis
24. Phenotypic characterization of 3H-thymidine incorporating cells in rheumatoid arthritis synovial membrane
25. Enrichment of differentiated CD45RBdim, CD27- memory T cells in the peripheral blood, synovial fluid, and synovial tissue of patients with rheumatoid arthritis
26. Distribution of CD45RA and CD45RO T-lymphocyte subsets in rheumatoid arthritis synovial tissue
27. Role of cytokines in rheumatoid arthritis
28. In situ hybridization of interleukin-1 in CD14-positive cells in rheumatoid arthritis
29. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis
30. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases
31. Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids
32. IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium
33. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis
34. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency
35. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis
36. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra
37. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis
38. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts
39. Cathepsin B in synovial cells at the site of joint destruction in rheumatoid arthritis
40. Immunohistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenvironment
41. Adhesion molecule expression in human synovial tissue
42. Morphometric analysis of blood vessels in synovial membranes obtained from clinically affected and unaffected knee joints of patients with rheumatoid arthritis
43. Angiogenesis: Implications for rheumatoid arthritis
44. The effectiveness of early treatment with "second-line" antirheumatic drugs: A randomized, controlled trial
45. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study
46. Economic burden of rheumatoid arthritis: A systematic review
47. Long-term outcome of treating rheumatoid arthritis: Results after 20 years
48. Mortality and survival in rheumatoid arthritis: A 25 year prospective study of 100 patients
49. American College of Rheumatology: Preliminary definition of improvement in rheumatoid arthritis
50. Development of a disease activity score based on judgment in clinical practice by rheumatologists
51. Measurement of patient outcome in arthritis
52. Clinical economics: A guide to the economic analysis of clinical practices
53. A radiological method for grading the severity of rheumatoid arthritis
54. Radiologic assessment as an outcome measure in rheumatoid arthritis
55. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: Results of two metaanalyses
56. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice
57. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II, second line drugs and prednisone
58. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: A metaanalysis of published clinical trials
59. Guidelines for monitoring drug therapy in rheumatoid arthritis
60. Clinical improvement and radiological deterioration in rheumatoid arthritis: Evidence that the pathogenesis of synovial inflammation and articular erosion may differ
61. Longterm prospective study of methotrexate in rheumatoid arthritis: Conclusion after 132 months of therapy
62. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: Followup after a mean of 13.3 years
63. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial
64. The effects of drug therapy on radiographic progression of rheumatoid arthritis: Results of a 36-week randomized trial comparing methotrexate and auranofin
65. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis
66. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study
67. Treatment of rheumatoid arthritis with methotrexate: A prospective open longterm study of 191 cases
68. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: A controlled clinical trial
69. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: A controlled clinical trial
70. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis
71. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
72. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
73. Infliximab and methotrexate in the treatment of rheumatoid arthritis
74. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
75. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis
76. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications
77. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
78. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial
79. 54 week clinical and radiographic results from the ATTRACT trial: A phase III study of infliximab (Remicade) in patients with active RA despite methotrexate
80. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms
81. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis
82. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
83. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate
84. Two year treatment of active rheumatoid arthritis (RA) with leflunomide (LEF) compared with placebo (PL) or methotrexate (MTX)
85. The combination of leflunomide and methotrexate in patients with active rheumatoid arthritis who are failing on methotrexate treatment alone: A double-blind placebo controlled study
86. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: Results of a randomized, placebo-controlled, phase II study
87. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis
88. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial
89. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
90. Long-term safety and efficacy of combination therapy with methotrexate (MTX) and etancercept (Enbrel)
91. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
92. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
93. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy